Cytiva has introduced its Supor Prime sterilizing grade filters to address filtration needs of customers manufacturing high-concentration biologic drugs. The Supor Prime filter is designed to help drug developers achieve higher yields, reduce premature blockages, and limit the costs associated with filtration losses.

The trend toward high-concentration biologics is mainly driven by a surge in demand for subcutaneous drugs that can be self-administered, reducing the need for intravenous injections at hospitals and clinics.

The complex formulation and consistency of high-concentration biologic drugs makes it more difficult to filter the drug product, while its high particle load often leads to premature filter blockage. Drug developers have often compensated with oversized or additional filters to address this challenge, but that can lead to increased hold-up volume resulting in costly drug product losses.

Cytiva’s Supor Prime filters are designed to deliver high throughput capacity for high-concentration biologic feeds up to 220 grams per liter of concentration and 30 centipoise viscosity, resulting in increased drug product recovery in the final manufacturing steps. The filters are also designed to scale-up from clinical development to commercial manufacturing.